Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xeros
- Development stage
- Phase 4
- Lead developer
- Dentaid
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Xeros is a brand of topical oral care products developed by Dentaid, primarily indicated for the symptomatic relief of xerostomia (dry mouth) and hyposalivation. One notable product under this brand, Xeros Dentaid Spray, is a combination formulation containing 1% malic acid, 10% xylitol, and 0.05% fluoride. Malic acid acts as a sialogogue, stimulating natural saliva production, while xylitol and fluoride contribute to oral health by inhibiting bacterial metabolism and strengthening tooth enamel, respectively, which are crucial benefits for individuals experiencing reduced salivary flow.
- Brand names
- Xeros Dentaid SprayXeros Dentaid systemDentaid Xeros
- Other names
- Xeros Dentaid system
Beyond the preview
Go deeper on Xeros.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xeros.